These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 1208766)

  • 1. Treatment of Sydenham's chorea with a combination of L-dopa and a peripheral dopa decarboxylase inhibitor.
    Spissu A; Corsini GU; Marrosu F; Mangoni A
    Psychopharmacologia; 1975 Nov; 44(3):311-2. PubMed ID: 1208766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homovanilic acid in Huntington's disease and Sydenham's chorea.
    Cunha L; Oliveira CR; Diniz M; Amaral R; Conçalves AF; Pio-Abreu J
    J Neurol Neurosurg Psychiatry; 1981 Mar; 44(3):258-61. PubMed ID: 6453208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Decarboxylase inhibitors combined with L-dopa in the treatment of Parkinson's disease].
    Rondot P
    Rev Prat; 1974 Mar; 24(15):1211-2, 1215-6, 1219. PubMed ID: 4416964
    [No Abstract]   [Full Text] [Related]  

  • 4. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
    Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
    Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone in Parkinson's disease.
    Lieberman A; Goodgold A; Jonas S; Leibowitz M
    Neurology; 1975 Oct; 25(10):911-6. PubMed ID: 1101099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of "on-off effect" with a dopa decarboxylase inhibitor.
    Sweet RD; McDowell FH; Wasterlain CG; Stern PH
    Arch Neurol; 1975 Aug; 32(8):560-3. PubMed ID: 1156214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of studies on the treatment of parkinsonian syndromes with levodopa. II. Long-term effects of L-DOPA alone or in combination with a decarboxylase inhibitor].
    Rabadeau Dumas JL; Rondot P; Cardon P
    Therapie; 1977; 32(2):161-72. PubMed ID: 898124
    [No Abstract]   [Full Text] [Related]  

  • 8. [CB 154 in the treatment of Parkinson's disease. Results in combination with L-dopa and decarboxylase inhibitor].
    Meco G; Casacchia M; Zamponi A; Agnoli A
    Acta Neurol (Napoli); 1976; 31(4):479-48. PubMed ID: 1037427
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment of Parkinson's disease with levodopa and a dopa decarboxylase inhibitor].
    Londoõ R
    Neurol Neurocir Psiquiatr; 1976; 17(4):293-300. PubMed ID: 1018729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term treatment of Parkinson's disease with L-Dopa and Dopa-decarboxylase inhibitor: therapeutic results and side effects.
    Battistin L; Meneghetti G; Rigotti S; Saia A
    Acta Neurol Scand; 1978 Feb; 57(2):186-92. PubMed ID: 347868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical picture and plasma levodopa metabolite profile of parkinsonian nonresponders. Treatment with levodopa and decarboxylase inhibitor.
    Rivera-Calimlim L; Tandon D; Anderson F; Joynt R
    Arch Neurol; 1977 Apr; 34(4):228-32. PubMed ID: 843257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Niacin depletion in Parkinsonian patients treated with L-dopa, benserazide and carbidopa.
    Bender DA; Earl CJ; Lees AJ
    Clin Sci (Lond); 1979 Jan; 56(1):89-93. PubMed ID: 477187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of Parkinson's disease with the combination drug L-carbidopa/L-dopa. Report on a 2 years study].
    Hayek J
    Schweiz Med Wochenschr; 1977 Apr; 107(14):474-9. PubMed ID: 847450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levodopa with benserazide or carbidopa in Parkinson disease.
    Rinne UK; Mölsä P
    Neurology; 1979 Dec; 29(12):1584-9. PubMed ID: 574221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of Parkinson's syndrome with L-dopa and L-carbidopa (author's transl)].
    Hanzal F
    MMW Munch Med Wochenschr; 1976 May; 118(20):653-6. PubMed ID: 818540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of apomorphine and apomorphine-L-dopa-carbidopa on alcohol post-intoxication symptoms.
    Wadstein J; Ohlin H; Stenberg P
    Drug Alcohol Depend; 1978 Jul; 3(4):281-7. PubMed ID: 357128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of clinical symptoms, HVA and 5-HIAA in csf and plasma L-DOPA in Parkinsonian patients treated with L-DOPA and L-DOPA + RO 4-4602.
    Campanella G; Algeri S; Cerletti C; Dolfini E; Jori A; Rinaldi F
    Eur J Clin Pharmacol; 1977 Apr; 11(4):255-61. PubMed ID: 862646
    [No Abstract]   [Full Text] [Related]  

  • 18. Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's disease.
    Ruggieri S; Falaschi P; Baldassarre M; D'Urso R; De Giorgio G; Rocco A; Agnoli A
    Neuropsychobiology; 1982; 8(2):102-8. PubMed ID: 7070643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Controlled study on the possibilities of L-dopa in the residual extrapyramidal syndrome caused by neuroleptics].
    Gutiérrez M; Alpert M; Guimón J; Friedhoff AJ; Veramendi V
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1979; 7(3):181-8. PubMed ID: 382762
    [No Abstract]   [Full Text] [Related]  

  • 20. Alpha methyldopahydrazine as an adjunct to levodopa therapy in Parkinson's disease.
    Paty DW; Jaatoul N; Kertesz A; McInnis W
    Can J Neurol Sci; 1975 Aug; 2(3):169-72. PubMed ID: 1100213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.